IMR Press / EJGO / Volume 34 / Issue 1 / pii/1630905361224-777922104

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma

Show Less
1 Center of Medical Biochemistry, Clinical Center of Serbia, Belgrade
2 School of Medicine, University of Belgrade, Clinic of Gynecology and Obstetrics, Clinical Center of Belgrade, Belgrade
3 Clinic of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade
4 Faculty of Pharmacy, Department of Analytical Chemistry, University of Belgrade (Serbia)
Eur. J. Gynaecol. Oncol. 2013, 34(1), 83–85;
Published: 10 February 2013

The objective of this study was to determine the potential of osteopontin (OPN) and OPN + CA125 (cancer antigen 125) combination in differential diagnosis of the ovarian cancers and non-malignant ovarian disease. Serum and plasma samples were obtained preoperatively from 79 women undergoing surgery for pelvic mass; 48 of them had ovarian carcinoma, and 31 had benign cyst. The samples were analyzed for the levels of OPN and CA125 (using ELISA and CMIA methods) and then compared with the final pathologic results. The median plasma level of OPN in patients with benign and malignant cysts was 356.33 ng/ml and 865.15 ng/mL, respectively (p < 0.001). Receiver operating characteristic (ROC) analysis for plasma OPN revealed the area under the curve (AUC) of 0.838. At the predefined specificity of 90%, OPN showed sensitivity of 62.5%, whereas the combination of OPN + CA125 reached 74.9% at the same specificity.
Ovarian cancer
Tumor markers
Back to top